{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015710","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.702525+00:00","generated_at":"2026-06-22T20:28:21.639360+00:00","sec_items":["2.02","5.03","5.07","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne Q1 FY2023 revenue up 7% organic, GAAP EPS $2.21, declares 4-for-1 stock split","bullets":["Total revenue $269.7M, up 5% reported / 7% organic YoY.","GAAP diluted EPS $2.21 (vs $1.69); adjusted diluted EPS $1.78 (vs $1.83, FX impact $0.12).","Diagnostics & Genomics segment organic growth of 17%; ExoDx Prostate test revenue +100% YoY.","Operating cash flow $56.1M, up 16% YoY.","Board declared $0.32/share quarterly cash dividend (payable Nov 28) and 4-for-1 stock split (distributed Nov 29, trading split-adjusted Nov 30)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015710","json":"https://secwatch.observer/filing/0001558370-22-015710.json","markdown":"https://secwatch.observer/filing/0001558370-22-015710.md","text":"https://secwatch.observer/filing/0001558370-22-015710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/tmb-20221027x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:28:21.639360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"938f0aeb3e3d19229a9a5a9dd4c46f61468043e5","claim":"BIO-TECHNE Corp: Increased authorized shares of common stock from 100,000,000 to 400,000,000 (effective 2022-10-27).","evidence_excerpt":"At the 2022 annual meeting of shareholders of the Company held on October 27, 2022 (the “Annual Meeting”), the shareholders approved an amendment and restatement of the Company’s articles of incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-10-27"}],"fact_type":"governance_change"},{"claim_id":"0af67227612377887b89742a08e4e9e6f798f11a","claim":"BIO-TECHNE Corp shareholders approved The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement at the 2022-10-27 meeting.","evidence_excerpt":"Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: For Against Abstain Broker Non-Vote 21,321,031 13,045,755 286,774 1,070,883","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-27"}],"fact_type":"shareholder_vote"},{"claim_id":"35ae5e91c9b5dd965c1ac73fc768597b5aafaf1c","claim":"BIO-TECHNE Corp shareholders approved The shareholders ratified an amendment to increase the number of shares of authorized common stock at the 2022-10-27 meeting.","evidence_excerpt":"Proposal No. 4 – The shareholders ratified an amendment to increase the number of shares of authorized common stock. For Against Abstain ​ 35,648,572 68,310 7,561","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-27"}],"fact_type":"shareholder_vote"},{"claim_id":"8010b9b2be00b15dcc3ab0bb1f5074bb6fb427e3","claim":"BIO-TECHNE Corp shareholders approved The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023 at the 2022-10-27 meeting.","evidence_excerpt":"Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023. For Against Abstain ​ 34,862,262 856,480 5,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-27"}],"fact_type":"shareholder_vote"},{"claim_id":"b93f130b0e8fa255f87bf01f742b7370e07c3d51","claim":"BIO-TECHNE Corp shareholders approved The shareholders elected each of the nominees to the Board of Directors at the 2022-10-27 meeting.","evidence_excerpt":"Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: ​ For Against Abstain Broker Non-Vote Charles R. Kummeth 34,092,428 546,544 14,588 1,070,883 Robert V. Baumgartner 24,822,872 9,195,158 635,530 1,070,883 Randolph C. Steer 31,246,852 3,392,776 13,932 1,070,883 John L. Higgins 27,963,915 6,675,747 13,898 1,070,883 Roeland Nusse 33,805,594 834,332 13,634 1,070,883 Julie L. Bushman 34,398,791 242,354 12,415 1,070,883 Joseph D. Keegan 32,918,324 1,721,906 13,330 1,070,883 Alpna Seth 33,163,651 1,475,674 14,235 1,070,883 Rupert Vessey 32,917,182 1,721,925 14,453 1,070,883 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-27"}],"fact_type":"shareholder_vote"},{"claim_id":"bfd21a14bc67d11faa918d3f5050591f592abd64","claim":"BIO-TECHNE Corp shareholders approved The shareholders voted to set the number of directors at nine at the 2022-10-27 meeting.","evidence_excerpt":"Proposal No. 1 – The shareholders voted to set the number of directors at nine: ​ For Against Abstain ​ 35,575,971 139,956 8,516","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837022015710/0001558370-22-015710-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-10-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}